Clinical Trial Update: Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose thalidomide for myelodysplastic syndromes has completed. No efficacy or safety results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED